Pluripotent Stem Cell T Cell Generation Without Thymus Fragments
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining T cells, particularly regulatory T cells (Treg) and effector T cells (Teff), from pluripotent stem cells are inefficient and require thymus fragments, which are not suitable for therapeutic applications in humans, and lack effective protocols for significant TCR expression in Teff cells and CD4−CD8−CD3+TCRab+ T cells.
Innovation Solution
A method involving culturing pluripotent stem cells to form embryoid bodies, dissociating them, and coculturing with Notch ligands, while introducing a vector encoding Foxp3, to generate T cells, including Treg, Teff, and CD4−CD8−CD3+TCRab+ cells, using a serum-free medium with growth factors like BMP, FGF2, VEGF, SCF, Flt3-L, and IL-3, and transducing cells with a nucleic acid sequence encoding Foxp3 or a chimeric antigen receptor (CAR) using lentiviral vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If thymus fragments are used in current protocols, then T cell generation is enabled, but the method is not suitable for therapeutic applications in humans
Solution Approach 1:
The invention extracts and eliminates the requirement for thymus fragments from the T cell generation protocol. By using pluripotent stem cells as the starting material, the method removes the problematic component (thymus fragments) while maintaining the ability to generate functional T cells, thereby enabling therapeutic applications in humans.
Solution Approach 2:
The invention performs preliminary differentiation of pluripotent stem cells into hematopoietic progenitors before T cell commitment. This preliminary action creates a standardized starting population that can be consistently differentiated into T cells without requiring variable thymus fragments, improving both adaptability and reducing protocol complexity.
2Productivity
If conventional culture methods are used, then T cells can be obtained, but the quantity and efficiency are insufficient for therapeutic applications
Solution Approach 1:
The invention implements a dynamic, multi-stage differentiation protocol that adapts culture conditions at each stage. By transitioning from pluripotent stem cells to hematopoietic progenitors and then to T cell precursors under optimized conditions, the method dramatically increases T cell yield while managing culture time efficiently through staged expansion.
Solution Approach 2:
The invention systematically changes cultural parameters including growth factors, cell density, and differentiation cues at each stage. These parameter changes optimize each transition step, enabling high-yield T cell production. The method achieves sufficient quantities for therapy by accumulating cells through controlled parameter adjustments rather than extending culture time indefinitely.
3Manufacturing precision
If TCR expression is not optimized, then protocol simplicity is maintained, but significant TCR expression in Teff cells and CD4-CD8-CD3+TCRab+ T cells is not achieved
Solution Approach 1:
The invention introduces the TCR transgene into pluripotent stem cells before differentiation begins. This preliminary genetic modification ensures that all subsequently generated T cells will express the desired TCR, achieving high manufacturing precision without requiring complex post-differentiation selection or transduction steps.
Solution Approach 2:
The differentiation protocol is designed to be universally applicable to generating multiple T cell subsets (Teff, Treg, and CD4-CD8-CD3+TCRab+ T cells) from a single transduced pluripotent stem cell population. This multi-functionality achieves high TCR expression across all subsets through a single integrated protocol rather than separate procedures for each cell type.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the production of T cells with therapeutic potential for immune dysregulation disorders, autoimmune diseases, inflammatory diseases, cancer, and graft rejection, by achieving significant expression of TCR and CAR, allowing for large-scale production of functional T cells without the need for thymus fragments.
Implementation Method 1
transducing cells with a nucleic acid sequence encoding Foxp3 or a chimeric antigen receptor (CAR) using lentiviral vectors
Implementation Method 2
coculturing with Notch ligands, while introducing a vector encoding Foxp3, to generate T cells
Implementation Method 3
using a serum-free medium with growth factors like BMP, FGF2, VEGF, SCF, Flt3-L, and IL-3
Data Source
AI summary
A method for obtaining a population of T cells from pluripotent stem cells, which includes a first step of obtaining hematopoietic stem cells and a second step of obtaining T cells. Also, the cell populations thus obtained according to this method and these cell populations for use as a medicament.